05:16 AM EDT, 08/07/2025 (MT Newswires) -- Absci ( ABSI ) and Almirall said Thursday that they have agreed to expand their ongoing artificial intelligence drug discovery collaboration to include a second program.

Under the partnership, Almirall will select a second target focused on dermatological indications.

Absci ( ABSI ) said it is entitled to receive up to about $650 million in upfront and milestone payments across both programs under the collaboration, plus royalties on potential sales.

The collaboration, which was announced in November 2023, combines Absci's ( ABSI ) Integrated Drug Creation platform with Almirall's experience in developing therapeutics for chronic and debilitating skin diseases, the companies said.